Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. An innovative in situ cell reprogramming technology for cancer treatment

    SBC: QURGEN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Development of a Neuroprotective Agent For Cerebral Palsy Prevention

    SBC: Zietchick Research Institute, LLC            Topic: NICHD

    DESCRIPTION (provided by applicant): Cerebral palsy (CP), the most common physical disability in childhood, afflicts more than 800,000 Americans and many more worldwide. In addition to motor difficulties, many children with CP also suffer from intellectualdisability, epilepsy, nutritional problems, and language dysfunction. Furthermore, almost 90% of CP-associated brain injuries occur in utero or ...

    STTR Phase I 2014 Department of Health and Human Services
  3. TruEnamel: A dental product that treats, protects, desensitizes and whitens teeth

    SBC: TruEnamel, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Dentin hypersensitivity is a painful condition affecting from of the population It is caused by the movement of fluid in the dentinal tubules and can be eliminated by occluding these patent tubules Tooth whitening is a $ billion business in America and is predicted to grow both here and abroad In this grant we propose a treatment for dentin hypers ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Advanced Nitric Oxide Release Bactericidal Urinary Catheters

    SBC: BIOCREDE INC.            Topic: 300

    DESCRIPTION provided by applicant In Phase I Biocrede developed a completely new urinary tract silicone Foley catheter with a andgt month shelf life made from a proprietary polymeric formulation to effectively reduce catheter associated urinary tract infections CAUTI via nitric oxide NO release for andgt weeks Key features of the new technology include catheters continuously d ...

    STTR Phase II 2015 Department of Health and Human Services
  5. Validation and Cryopreservation of Ligament Engineered from Human Bone Marrow

    SBC: STEL Technologies, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The founders of Skeletal Tissue Engineering Laboratory Technologies LLC STEL are researchers at the University of Michigan Our research team has developed an innovative and paradigm shifting approach to ligament tissue engineering and a unique methodology for ACL replacement This tissue engineered ligament technology offers the possibility of radical impr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. S-Nitrosothiol-Based Rinse/Aerosol Solutions For Treatment/Prevention of Rhinosinusitis

    SBC: NOTA Laboratories LLC            Topic: NIAID

    DESCRIPTION provided by applicant The purpose of the research being proposed is to develop a highly effective nasal rinse that can treat chronic rhinosinusitis CRS in an entirely new way Often CRS is overlooked because it is rarely life threatening CRS is estimated to affect an astounding of the US population with direct costs exceeding $ billion annually and additionally causing ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Family Supportive Supervisor Training and Workplace Assessment Tool

    SBC: WORK LIFE HELP, INC.            Topic: NIA

    DESCRIPTION provided by applicant Managing the demands of work and personal life is a major stressor affecting employees yet there are virtually no evidence based workplace supervisory training interventions to address this critical public health concern Research has shown work family conflict can affect employeesandapos health workplace productivity family interactions and safety and wel ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Development of MTX for the Treatment of KRAS Mutant Colorectal Cancer

    SBC: Mekanistic Therapeutics, LLC            Topic: NCI

    PROJECT SUMMARY Mekanistic Therapeutics seeks to design discover and develop anti cancer agents that selectively inhibit multiple oncogenic pathways Its lead agent MTX was discovered in collaboration with the Leopold laboratory at University of Michigan MTX is a novel kinase inhibitor showing early promise for its therapeutic potential against solid cancers refractory to current treatm ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A nanoparticle delivery system for CRISPR Cas based therapeutics

    SBC: ATGC Inc.            Topic: NCATS

    Abstract Applications of customizable nucleases such as CRISPR clustered regularly interspaced short palindromic repeats Cas CRISPR associated protein have enabled efficient and precise gene correction in vitro and hold promises for eventually achieving in vivo gene correction therapy However to apply CRISPR Cas in therapeutic settings several major challenges remain to be addressed ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Fc folate Conjugate for the Treatment of Triple Negative Breast Cancer

    SBC: NeuLink Inc.            Topic: 100

    Abstract According to the American Cancer Society in women in the U S will develop breast cancer at some point in their life and of these women will have triple negative breast cancer TNBC an aggressive subtype of breast cancer that lacks the three receptors ER PR HER that current drug treatment targets tamoxifen Herceptin Because of its aggressive nature and lack of effec ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government